Home World News OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced... World News OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 816 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations July 21, 2022 April is Occupational Therapy (OT) Month- What is OT and how... April 8, 2021 Time to meet our new chief scientist – Professor KJ Patel October 12, 2022 New analysis reveals Black women in England more likely to be... January 27, 2023 Load more HOT NEWS Favourable Results of Patritumab Deruxtecan in Patients with Leptomeningeal Metastatic Disease... Cancer in My Community: The Role of Cancer Screening in Guatemala New Approach Uses Much Less Tissue to Analyze Tumor Proteins and... FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell...
